Standard Lipid Panel Components
A standard lipid panel measures five core components: total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), and triglycerides 1, 2.
Core Lipid Panel Components
The Canadian Society of Clinical Chemists explicitly recommends that clinical laboratories offer a lipid panel consisting of these five parameters 1, 2:
- Total cholesterol (TC) - measures all cholesterol in the blood
- LDL cholesterol (LDL-C) - typically calculated using equations rather than directly measured
- HDL cholesterol (HDL-C) - the "protective" cholesterol
- Non-HDL cholesterol (non-HDL-C) - calculated as total cholesterol minus HDL-C, representing total atherogenic burden
- Triglycerides (TG) - fat molecules in the blood
These five parameters form the foundation for cardiovascular risk assessment and treatment decisions 3.
Additional Tests Available Separately
Lipoprotein(a) [Lp(a)] and Apolipoprotein B (ApoB) should be offered only as individually orderable tests, not as part of the standard panel 1, 2. These are typically requested by specialists (lipidologists, endocrinologists, cardiologists) in specific clinical scenarios:
- Lp(a) - useful when there is premature vascular disease without obvious risk factors, family history of premature CVD, or suspected familial hypercholesterolemia 1
- ApoB - superior to LDL-C for therapeutic decision-making but adds analytical cost 4
Important Technical Details
Fasting vs. Non-Fasting
Modern guidelines support non-fasting lipid assessment for routine screening 1, 5. The maximal mean changes after habitual meals are not clinically significant (triglycerides increase by only 0.3 mmol/L or 26 mg/dL) 5. However, fasting assessment is required for diagnosis and pharmacological therapy decisions, using the average of at least 2 fasting profiles obtained 2 weeks to 3 months apart 1.
LDL-C Calculation
LDL-C is calculated rather than directly measured. The newer NIH equation is superior to the traditional Friedewald equation, particularly for non-fasting samples, high triglycerides (up to 9.04 mmol/L), and low LDL-C (down to 0.50 mmol/L) 2.
Non-HDL-C Superiority
Non-HDL-C appears superior to LDL-C for predicting CVD risk because it accounts for the total atherogenic particle burden, including not only LDL-C but also triglyceride-rich lipoproteins and their remnants 1.
Common Pitfall
A significant discordance exists between LDL-C and ApoB concentrations in approximately 24% of patients 6. When LDL-C and ApoB are discordant, ApoB more accurately reflects atherogenic burden and should guide treatment decisions 4.